Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics
March 15, 2021 07:00 ET
|
Renalytix AI plc.
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...
Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights
March 04, 2021 13:00 ET
|
Renalytix AI plc.
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...
RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021
March 02, 2021 07:00 ET
|
Renalytix AI plc.
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on...
The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health
February 24, 2021 08:00 ET
|
Renalytix AI plc.
NEW YORK and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of...
RenalytixAI to announce Financial Results for six and three months ended December 31, 2020
February 23, 2021 02:00 ET
|
Renalytix AI plc.
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), the artificial intelligence-enabled in vitro diagnostics company, focused on...
American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health
February 04, 2021 07:00 ET
|
Renalytix AI plc.
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of...
Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics
January 13, 2021 02:00 ET
|
Renalytix AI plc.
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway (RIN:...
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
January 05, 2021 06:00 ET
|
Renalytix AI plc.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and...
RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 08:05 ET
|
Renalytix AI plc.
NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of...
RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021
November 25, 2020 07:00 ET
|
Renalytix AI plc.
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of...